ELECTRIC · Efficacy of Leveraging Endocrine Therapies for Renoprotection during Intensive Care
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2021-06-01 → 2024-05-31
- EU contribution
- €277,260
- Participants
- 2
- Scheme
- MSCA-IF
Lines connect the coordinator with its partners.
Results in brief
Efficacy of Leveraging Endocrine Therapies for Renoprotection during Intensive Care
Problem/Issue Being Addressed: This project targets acute kidney injury (AKI) in ICU patients, specifically in sepsis or cardiac surgery cases. AKI affects over 50% of ICU patients and is associated with high mortality and long-term morbidity. Currently, AKI is diagnosed by renal function deterioration using plasma creatinine or urine output. The exact cause of AKI is unclear, but renal medulla hypoxia is thought to play a key role. Why is it Important for Society? AKI in the ICU is a significant issue, with serious consequences, including high mortality and potential progression to end-stage renal disease. Improving AKI prevention and management is critical to enhancing ICU care, reducing healthcare burdens, and saving lives. Overall Objectives: The project aims to evaluate the effectiveness of two renoprotective agents—GLP-1 receptor agonists (GLP-1 RA) and SGLT2 inhibitors (SGLT2i)—in preventing and reducing AKI in the ICU. The key objectives are: Assess GLP-1 receptor activation and SGLT2 inhibition effects on kidney perfusion, oxygenation, and injury markers in an ovine septic shock-induced AKI model. Evaluate SGLT2i effects on kidney perfusion and oxygenation using imaging in healthy humans. Examine SGLT2i impact on AKI markers in cardiac surgery patients. Conclusions of this Action: WP1+2. GLP-1 and SGLT2i did not show renoprotective effects in an ovine sepsis-AKI model. Sepsis-induced AKI may be too severe for these treatments. 3. Long-term SGLT2i treatment in diabetic patients improved kidney perfusion and oxygenation. 4. Short-term SGLT2i before and after cardiac surgery reduced postoperative AKI risk. A large multicenter trial has been initiated.
Data: CORDIS, © European Union
Project objective
On the intensive care unit, more than 50% of patients have acute kidney injury, and these patients suffer higher mortality and long-term morbidity. To date, no specific therapies exist to prevent or treat acute kidney injury on the intensive care unit. We now have two new endocrinologic agents, glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors, able to protect patients with diabetes from chronic kidney disease. The objective of this action is to investigate whether the renoprotective mechanisms of these agents can reduce markers of acute kidney injury in patients on the intensive care unit. This action incorporates a highly sophisticated animal model for the essential invasive measurement of renal physiology. To translate these findings to the clinical situation, I will employ new and innovative measurement techniques such as urinary oxygenation, new kidney biomarkers and advanced renal imaging techniques to elucidate these renoprotective mechanisms in humans. The involved universities of Amsterdam and the University of Melbourne bring together world leading experts on acute kidney injury, endocrinologic therapies, and intensive care medicine. By connecting their expertise, this action will not only provide insight into the renoprotective properties of the studied interventions and so improve the outcome of patients, but also train me as a researcher able to improve renal outcomes beyond the scope of this action.
Original text from CORDIS.
Participants
- STICHTING AMSTERDAM UMC · AmsterdamCoordinatorNetherlands
- MELBOURNE HEALTH · ParkvilleAustralia
Links
Data: CORDIS, © European Union